Donna Hoss-Green
Family · Newport News, VANPI 1467643163
Payments from drug & device makers
Across 164 payments — averaging $19.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$903
- AbbVie$256
- Endo Pharmaceuticals Inc.$247
- Bayer$218
- Blue Earth Diagnostics$211
- Urovant Sciences Inc$202
- plus $1K from 18 others
What the payments were for
- Food & beverage$2,89189%
- Education$36411%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 30 | $903 |
| AbbVie | 14 | $256 |
| Endo Pharmaceuticals Inc. | 13 | $247 |
| Bayer | 11 | $218 |
| Blue Earth Diagnostics | 9 | $211 |
| Urovant Sciences Inc | 12 | $202 |
| Axonics, Inc. | 8 | $181 |
| Antares Pharma, Inc. | 9 | $162 |
| Myovant Sciences Inc. | 8 | $139 |
| Coloplast | 6 | $101 |
| Sumitomo Pharma America, Inc. | 5 | $88 |
| Clarus Therapeutics Inc. | 13 | $85 |
| Pfizer | 5 | $82 |
| Teleflex LLC | 2 | $73 |
| Myriad Genetic Laboratories, Inc. | 4 | $54 |
| Rochester Medical Corporation | 3 | $49 |
| Merck | 2 | $44 |
| Kowa Pharmaceuticals America, Inc. | 3 | $43 |
| Urogen Pharma, Inc. | 2 | $41 |
| AstraZeneca | 1 | $16 |
| Vanda Pharmaceuticals Inc. | 1 | $16 |
| Hollister Incorporated | 1 | $15 |
| Dexcom, Inc. | 1 | $14 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,255 in reported general payments places this provider in the 85th percentile of 4,332 family providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 17 | $5,700 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $903 | $5,70017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,332 family providers in Virginia.
Other family in Newport News
- Rosemarie McFatherNewport News$13K
- Sabrina BrownNewport News$11K
- Andrea CottonVirginia Beach$696K
- Susan MooreWytheville$438K
- Ellen WermterCharlottesville$251K
- Dana StallingsFranklin$225K
- Jocelyn BrackettHerndon$199K
- Hochong Smith GillesRichmond$131K
- Sean OlaughlinMidlothian$110K
- Adam MedlinHampton$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.